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Recent advances suggest that phase transitions of proteins into liquid or hydrogel states could underlie
pathological protein aggregation associated with neurodegenerative disease. In a recent issue of Neuron,
Murakami et al. (2015) demonstrate that ALS-associated FUS mutations abrogate the reversibility of
condensed liquids and/or hydrogels, leading to neurotoxicity in C. elegans.Many neurodegenerative diseases,
including Alzheimer’s disease, Parkin-
son’s disease, and amyotrophic lateral
sclerosis (ALS), are marked by the forma-
tion of insoluble protein aggregates
throughout the nervous system. However,
an understanding of the biogenesis of
protein aggregation and the mechanism
by which the aggregation process im-
pacts neuronal dysfunction remains
elusive. RNA-binding proteins such as
FUS, TDP-43, and hnRNPA1 are impli-
cated in pathological aggregation in ALS
and fronto-temporal dementia (FTD).
Interestingly, these proteins normally
function in the assembly of stress gran-
ules, RNA/protein (RNP) assemblies that
exhibit dynamic liquid-like behavior. In a
recent issue of Neuron, Murakami et al.
(2015) demonstrate that ALS-associated
FUSmutations contribute to neurotoxicity
by promoting the formation of irreversible
protein phases (Figure 1).
Phase transitions of proteins into
condensed liquid or hydrogel states is
emerging as a ubiquitous process under-
lying intracellular organization and its
pathological dysregulation. Intrinsically
disordered protein (IDP)/low complexity
(LC) domains of RNA-binding proteins
have been shown to drive phase transi-
tions into either liquid droplets or hydro-
gels. In agreement with several other
reports (Altmeyer et al., 2015; Burke
et al., 2015; Lin et al., 2015; Patel et al.,
2015; Xiang et al., 2015), Murakami et al.
(2015) show that FUS can phase-separate
into liquid droplets and hydrogels in a
manner dependent on its LC domain.
However, they find that FUS disease
mutants impact the degree of reversibility
of FUS phases. While WT FUS can cycle
between gel and solution states uponseveral cycles (5) of cooling and heating,
FUS gels assembled from G156E and
S96Del mutants could not be completely
reversed. Similarly, FUS WT liquid drop-
lets remix into a homogenous phase
upon warming, while FUSmutants do not.
A challenge facing this new field is to
connect in vitro protein phase behavior
with in vivo cellular and organismal pro-
cesses. Murakami et al. (2015) make
progress in bridging this gap by charac-
terizing solubility states and retention of
accessory proteins across FUS droplets,
gels, and assemblies of FUS protein ex-
pressed in the C. elegans nervous system
(Figure 1). Analysis of C. elegans lysates
revealed distinct features of WT and
mutant FUS assemblies in vivo: while
WT FUS is fully soluble in worm lysate pre-
pared in standard high-salt RIPA buffer,
harsh 8M urea treatment was required to
fully solubilize mutant FUS assemblies.
Notably, the degree of insolubility corre-
lates with a decrease in lifespan and
neuronal motor function measured by a
worm thrashing score. Using an RNAi
screen, two proteins associated with
neuronal toxicity, SMN and STAU-1,
were identified and found to colocalize
with FUS mutant assemblies, but not
wild-type FUS. Remarkably, both the
RIPA/urea solubility patterns and localiza-
tion of SMN and STAU-1 proteins are
mirrored in vitro, with the recombinant
FUS liquid droplets and hydrogels. The
authors conclude that retention of addi-
tional proteins within irreversible FUS
assembly states plays an important role
in neurotoxicity.
The work of Murakami et al. (2015)
is consistent with a flurry of recent
papers demonstrating that numerous
IDP/LC proteins drive phase separationDevelopmental Cell 35,into liquid droplets with malleable pro-
perties (Elbaum-Garfinkle et al., 2015;
Lin et al., 2015; Molliex et al., 2015; Nott
et al., 2015; Patel et al., 2015; Zhang
et al., 2015). The current work further sup-
ports the hypothesis that gelation of in vivo
liquid phase assemblies is associated
with neurodegeneration. The dynamics
of this process are challenging to dissect
in vivo. A newly described tool for assay-
ing protein conformational state both
in vitro and in vivo (Xiang et al., 2015)
could be useful for determining how liquid
phase assemblies may convert to patho-
logical fibers and/or gels in vivo. More
experiments are needed to decipher the
unique and shared characteristics of
phase-separated liquids and gels, as
well as their respective contribution to
function and pathology.
Most previous studies have reported
phase transitions into liquid droplets or
gels that are completely reversible, in
notable contrast to the irreversibly-
assembled amyloid fibers associated
with disease. However, the irreversible
FUS assemblies described by Murakami
et al. (2015) are also different from classic
amyloids in that they do not interact with
amyloid-sensitive dyes and are soluble
in urea. Thus, regardless of the structural
state of the protein within intracellular
assemblies, irreversibility may serve as a
more useful metric of toxicity for future
studies.
Biological function requires dynamic
molecular interactions. Irreversible,
solid-like protein assemblies are therefore
expected to have detrimental effects on
cellular function. Sequestering of proteins
and RNA could serve to repress transla-
tion or simply disrupt functions that
depend on the cytoplasmic abundanceDecember 7, 2015 ª2015 Elsevier Inc. 531
Figure 1. Model of FUS Protein Assemblies
FUSwild-type protein can assemble into liquid or hydrogel states that can be fully reversed to amixed bulk
solution. FUS ALS/FTD mutations lead to assembly of liquids and/or gels that can no longer be reversed,
resulting in the retention of additional proteins. This insoluble, irreversible protein phase correlates with
deteriorated motor nerve function and decreased lifespan, characteristic of ALS/FTD diseases.
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Previewsof particular proteins. To test whether
FUS mutant assemblies serve as transla-
tional repressors, Murakami et al. (2015)
demonstrate that mutant FUS neurons
experienced a significant reduction in
protein synthesis. This suggests that
mutant FUS assembliesmay be patholog-
ical due to sequestration of components
necessary for RNA metabolism and
translation.532 Developmental Cell 35, December 7, 201Moving forward, it will be exciting to
discern how liquid-phase RNP assem-
blies are regulated and maintained in vivo
to avoid irreversible pathological tra-
nsitions. The heterogeneous molecular
composition of in vivo assemblies is a
likely factor in avoiding pathogenicity.
RNA can tune the material properties of
RNP droplets (Elbaum-Garfinkle et al.,
2015; Zhang et al., 2015), suggesting5 ª2015 Elsevier Inc.that the presence or absence of RNA
could impact pathogenic aging of drop-
lets. It will also be interesting to see how
chaperone and disaggregase activity,
along with stress- or age-associated
proteostasis breakdown, could influence
droplet assembly and properties. Deter-
mining the biophysical and intracellular
regulatory mechanisms governing RNP
phase transitions into liquid and gel-like
states should lead to new approaches
for therapies aimed at inhibiting or
reversing neurotoxic protein aggregation.REFERENCES
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